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ABSTRACT:
S100A14 is an EF-hand calcium-binding protein that has been reported to be 
involved in the progression of many malignancies. However, its role in ovarian 
cancer has not yet been clarified. In this study, we investigated the significance of 
S100A14 expression in epithelial ovarian cancers (EOCs) as well as it’s mechanism of 
action. On both RNA and protein levels, S100A14 was overexpressed in transformed 
cells. Immunohistochemical staining demonstrated that S100A14 expression was 
associated with advanced stage (P < 0.001) and poor tumor grade (P < 0.001). 
Moreover, S100A14 overexpression was an independent prognostic factor for overall 
survival (HR = 4.53, P = 0.029). We also investigated S100A14’s functional role 
by employing lentiviral-mediated overexpression and knockdown in EOC cells. 
S100A14 overexpression promoted cell proliferation, tumorigenesis, migration, and 
invasion, whereas S100A14 knockdown inhibited these properties. TOV112D cells that 
overexpressed S100A14 also exhibited greater tumor growth potential in xenografted 
mice. S100A14 promoted such a malignant phenotype in EOC cells through the PI3K/
Akt pathway. Taken together, our data indicate that S100A14 has a crucial role in 
EOC progression, and its overexpression is associated with poor prognosis. Further 
study of S100A14’s molecular mechanisms may lead to the development of a novel 
therapeutic target for ovarian cancer.
INTRODUCTION
Ovarian cancer is the leading cause of death from 
gynecological malignancies in developed countries [1]. 
Despite their clinical importance, little is known about 
the early stages of development for this neoplasm, 
largely owing to the absence of adequate animal models, 
the clinical inaccessibility of human ovaries, and the 
unfortunate paucity of symptoms until higher stages. The 
most common form of ovarian cancer is epithelial ovarian 
cancer (EOC). EOCs are believed to originate from normal 
ovarian surface epithelium or from its derivatives, which 
include the crypts and inclusion cysts on the epithelial 
surface [2]. A series of recent evidence also suggest that 
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ovarian high-grade serous carcinoma (HGSC) originates 
from the fimbrial portion of the fallopian tube, which 
has been termed “serous tubal intraepithelial carcinoma” 
(STIC) [3-6]. Understanding the molecular basis of EOC 
should significantly refine the diagnosis and management 
of these tumors and eventually lead to the development 
of more specific and more effective treatment modalities.
S100 proteins, a large subgroup of the EF-hand 
protein family, are small calcium-binding proteins that can 
function as both intracellular and extracellular signaling 
molecules [7]. They exert a broad range of functions 
by modulating their subcellular localization and by 
interacting with specific target proteins responsible for 
the regulation of inflammation, cell growth, cell motility, 
cell survival, and apoptosis [7-9]. Altered expression of 
a large number of S100 proteins has been reported in 
various human malignancies [10]. In addition, some S100 
proteins, namely S100A2, S100A4, and S100P, have been 
implicated in tumor invasion and metastasis [11-13].
S100A14 has recently been identified as an S100 
calcium-binding protein with unknown biological 
function [14]. The S100A14 gene was originally cloned 
and characterized in human lung cancer cell line, but was 
found to be differentially expressed in a variety of cell 
types. It was also reported to be upregulated in several 
tumor types, including ovarian, lung, breast, and uterine 
cancer, but downregulated in others, such as kidney, colon, 
rectal, and esophageal cancer [14]. S100A14 has also 
been shown to play vital roles in bladder tumorigenesis 
and tumor progression [15]. S100A14 can also regulate 
oral squamous cell carcinoma cell invasion by modulating 
the expression of matrix metalloproteinase (MMP) 
1 and MMP9 [16]. However, the role of S100A14 in 
ovarian cancer development and its underlying molecular 
mechanisms remain unclear. We have previously identified 
S100A14 to be upregulated in EOC by microarray [17] 
and have confirmed this by real-time PCR. In this study, 
we further investigate the clinical significance and 
functional role of S100A14 in EOC.
RESULTS
High S100A14 expression correlates with poor 
prognosis in EOC
We previously observed that the transcription 
level of S100A14 was upregulated 7.85-fold in three 
EOC cell lines by microarray analysis [17]. To eliminate 
the possibility that S100A14 gene expression only 
occurred in newly established EOC cell lines in in vitro 
culture, we performed validation studies using PCR and 
immunohistochemistry (IHC) in various EOC cell lines 
and tissues. Reverse transcriptase-PCR (RT-PCR) and 
real-time PCR revealed thatS100A14 mRNA levels were 
abundantly expressed in ovarian cancer cell lines, except 
TOV112D, OVCA433, and YDOV-151, whereas S100A14 
expression was almost undetectable in HOSE cell lines 
(Fig. 1A). Lysates from HEK293T cells transfected with 
pCDH/S100A14 plasmids were loaded as a positive 
control. Expression of S100A14 at the protein level was 
confirmed by immunoblot (Fig. 1B). S100A14 was highly 
expressed in SNU840, RMUG-S, and YDOV-139 cell 
lines, but could not be detected in HOSE cell lines (Fig. 
1B). These observations suggest that S100A14 expression 
primarily occurs in fully transformed cells.
To determine whether S100A14 overexpression 
is linked to clinicopathological features of EOC, we 
performed IHC analysis of S100A14 in 104 ovarian tissue 
specimens. Most immunoreactivity was observed in the 
cytoplasm of malignant cells (Fig. 1C). Scoring results 
from IHC analyses are summarized in Supplementary 
Table 2. EOC tissues had higher S100A14 expression 
levels than in borderline, benign, or normal tissues (P 
< 0.001). Furthermore, S100A14 immunoreactivity 
significantly correlated with features also associated 
with poor prognosis, including tumor stage (P < 0.001), 
histologic subtype (P = 0.004), and tumor grade (P < 
0.001). Specifically, advanced stage including recurrence, 
serous histologic subtype, and poor differentiation 
correspond to higher IHC scores (Fig. 1D, Supplementary 
Table 1). To further analyze S100A14 expression in 
ovarian cancer, we combined seven microarray data 
sets (GSE55510, GSE55512, GSE27651, GSE14001, 
GSE14407, GSE28724, and GSE51373) downloaded from 
the GEO database according to the literature [14]. Overall, 
149 ovarian cancers from genome-wide gene expression 
data were available. As expected, we found that S100A14 
mRNA expression was significantly higher in ovarian 
cancer (n = 149) than in normal ovarian surface epithelium 
(n = 29) (P < 0.001).
We next examined the relationship between 
S100A14 expression and outcome. Clinicopathological 
and outcome information was available for 65 EOC 
patients. Tumor samples in six cases were obtained at 
recurrence and excluded from the survival analysis. The 
follow-up period of EOC ranged from 5 to 77 months with 
a mean of 30.8 months. Kaplan-Meier plots demonstrated 
that patients with advanced stage (III/IV) and patients 
whose tumors were S100A14+ (IHC score of 6) displayed 
significantly worse overall survival (P = 0.029 and P = 
0.011, respectively) (Fig. 1E, Supplementary Fig. 1A-1C). 
A Cox multivariate proportional hazards analysis showed 
that advanced stage (hazard ratio [HR] = 3.25, P = 0.038 
and HR = 4.31, P = 0.024, respectively) and S100A14+ 
status (HR = 3.10, P = 0.017 and HR = 4.53, P = 0.029, 
respectively) were independent prognostic factors of 
disease-free and overall survival (Table 1).
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Figure 1: S100A14 is highly expressed in human ovarian cancer cells and tissue specimens, and its expression correlates 
with tumor stage and outcome of disease. A. S100A14 mRNA levels were assessed using RT-PCR (upper panel) and real-time PCR 
(lower panel) in human ovarian surface epithelial (HOSE) cells and ovarian cancer cells. Expression of GAPDH was included as an internal 
loading control. Kruskal-Wallis analysis of variance and post hoc Dunn method revealed statistically significant differences between EOC 
and HOSE cell lines (P = 0.019). Each value is expressed as a mean of triplicate samples. The reference cell line, HOSE 311, was 
considered to have a value of 1. B. S100A14 protein levels were analyzed using immunoblot. GAPDH was included as an internal loading 
control. C. Representative immunohistochemical staining for S100A14 in formalin-fixed, paraffin-embedded EOC tissues. Bars: 100 µm. 
D. IHC staining scores of S100A14 in EOC samples were significantly higher than those of healthy controls, benign ovarian tumors, and 
borderline ovarian tumors (P < 0.001). E. When we combined seven microarray data sets from GEO database, S100A14 mRNA expression 
was significantly increased in ovarian cancer (n = 149) when compared to normal ovarian surface epithelium (n = 29) (P < 0.001). F. 
Kaplan-Meier plots for patients with epithelial ovarian cancer were stratified according to S100A14 expression.
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Lentiviral-mediated overexpression and 
knockdown of S100A14 reveal that high S100A14 
expression increases cell proliferation and colony 
formation in EOC cells
Given that the biological function of S100A14 
in EOC is largely unknown, we set out to investigate 
the potential role of S100A14 in the development of 
a malignant phenotype in EOC cells by modulating 
intracellular S100A14 expression. We first established 
stable S100A14-overexpressed and -knocked down 
EOC cell lines by antibiotic selection of a pool of 
lentivirus-infected cells. For our S100A14 overexpression 
experiments, we used TOV112D and YDOV-151 cell 
lines, which have low levels of endogenous S100A14. 
Conversely, we used SNU840 and OVCA429 cell 
lines that have high levels of endogenous S100A14 
for our knockdown experiments. Strong S100A14 
immunoreactivity indicated excellent enrichment of 
S100A14 in TOV112D (S100A14 #6, #8) and YDOV-151 
(S100A14 #6, #10) cells when compared to empty vector-
transfected cells. Real-time PCR results were similar 
to those obtained from immunoblots, wherein higher 
S100A14 mRNA expression was shown in exogenous 
S100A14-expressing cells (Fig. 2A). In contrast, protein 
levels of S100A14 decreased by short-hairpin S100A14 
RNAi in SNU840 (sh-S100A14 #2, #5) and OVCA429 
(sh-S100A14 #2, #5) cells (Fig. 2B). Ultimately, the 
two most efficiently overexpressing or knocked down 
cell cultures for each cell type were selected to further 
investigate phenotypic changes arising from S100A14 
overexpression or downregulation.
We analyzed the effect of S100A14 overexpression 
in TOV112D and YDOV-151 using two assays to 
investigate short-term proliferative impact (WST-1 assay) 
and long-term proliferative ability (colony formation 
assay). In all S100A14-overexpressing cell lines, rates 
of cell growth were significantly higher than in empty 
vector-expressing controls (Fig. 3A). Similar results 
were also observed in colony formation assays (Fig. 3B). 
When S100A14 expression was repressed in SNU840 or 
OVCA429 cells, cell growth was not significantly altered 
by the WST-1 assay (Fig. 3C). However, knockdown 
of S100A14 significantly decreased colony formation 
in SNU840 and OVCA429 cells when compared to the 
shRNA-control group (Fig. 3D). We next performed 
a soft agar colony assay to assess S100A14’s role in 
tumorigenesis and found that the number of colonies 
formed from S100A14-transfected TOV112D cells was 
significantly higher than those resulting from empty 
vector-expressing controls (Fig. 3E). 
Lentiviral-mediated overexpression or 
knockdown of S100A14 reveals that high S100A14 
expression increase cell motility and invasion in 
EOC cells
To investigate whether S100A14 plays a role in 
migration in EOC cells, we conducted a wound-healing 
assay for cell migration. Overexpression of S100A14 
resulted in increased motility of TOV112D cells when 
compared to empty vector-expressing cells (Fig. 4A). 
In contrast, shRNA-mediated S100A14 knockdown 
inhibited cell motility in SNU840 cells (Fig. 4A). To 
evaluate whether S100A14 could also enhance invasion 
in EOC cells, a Matrigel invasion assay was performed. 
SNU840 and OVCA429, both of which have higher 
levels of endogenous S100A14, demonstrate significantly 
higher invasive potential than TOV112D and YDOV-
151, which both express endogenous S100A14 at much 
lower levels (Fig. 4B). To further confirm the possible role 
of S100A14 in cell invasion, we evaluated the invasive 
potential in TOV112D, YDOV-151, and OVCA429. 
S100A14 overexpression in TOV112D (S100A14#8) 
Table 1: Univariate and multivariate analyses of the associations between prognostic variables and disease-free (DFS) 
and overall survival (OS) in EOC patients.
DFS hazard ratio (95% CI), P value OS hazard ratio (95% CI), P value
Univariate Multivariate Univariate Multivariate
FIGO stage (III/IV) 4.78 [1.86-12.23], P=0.001
3.25 [1.07-9.92], 
P=0.038
4.84 [1.62-14.48], 
P=0.005
4.31 [1.20-15.44], 
P=0.024
Tumor grade (poor) 2.49 [1.11-5.59], P=0.026
1.03 [0.43-2.46], 
P=0.938 NS NA
Cell type (Serous) 4.49 [1.33-15.11], P=0.015
1.40 [0.36-6.41], 
P=0.665 NS NA
CA125+† NS NA NS NA
S100A14+‡ 6.74 [2.82-16.07], P=0.001
3.10 [1.22-7.89], 
P=0.017
6.42 [1.40-29.34], 
P=0.016
4.53 [1.16-17.69], 
P=0.029
CI, confidence interval; NS, not significant; NA, not applicable, CA125+† (> 35 U ml−1), S100A14+‡ (IHC score of > 5).
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and YDOV-151 (S100A14 #6, #10) resulted in increased 
invasion when compared to empty vector-expressing 
controls (Fig. 4C). In contrast, S100A14 knockdown in 
OVCA429 (sh-S100A14 #2, #5) cells led to a decrease in 
invasion capability (Fig. 4D). To explore the molecular 
mechanism behind S100A14’s promotion of cell migration 
and invasion, we characterized the expression of matrix 
metalloproteinase genes, MMP1, MMP2, and MMP9, 
by RT-PCR (Supplementary Fig. 2A). Interestingly, 
among the MMPs detected, expression of MMP1 and 
MMP9 was dramatically upregulated in S100A14-
overexpressed TOV112D cells. Real-time PCR analysis 
further confirmed the dramatic increase of MMP1 and 
MMP9 expression (Supplementary Fig. 2B). However, 
no significant difference in p53 expression was observed 
between S100A14-overexpressed cells and empty vector-
transfected cells (Supplementary Fig. 2C-D). Taken 
together, these results demonstrated that S100A14 plays 
an important role in cell motility and invasion.
Figure 2: Ectopic S100A14 expression and knockdown in lentivirus-mediated stable cells. A and B. Whole cell lysates and 
total RNA pool were collected from TOV112D (A, left : transfected with empty clone #4, #5 or S100A14 clone #6, #8), YDOV-151 (A, 
right : transfected with empty clone #4, #5 or S100A14 clone #6, #10). SNU840 (B, left: transfected with empty clone #7, #8 or S100A14 
shRNA sequence #2, #5), or OVCA429 (B, right: transfected with empty clone #3, #4 or S100A14 shRNA sequence #2, #5) stable cell lines. 
All shRNA sequences were different from each other. Expression of S100A14 protein was analyzed by immunoblot (upper panels), and 
mRNA level was measured by real-time PCR (lower panels). GAPDH was included as an internal loading control. An asterisk (*) indicates 
a p-value < 0.05, and a double asterisk (**), a p-value < 0.01.
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Figure 3: S100A14 increases cell proliferation and clonogenicity. A. Cell proliferation was determined by WST-1 assay. 
Cell proliferation curves for TOV112D and YDOV-151 cells at various indicated times. Error bars represent mean ± SD of triplicate 
experiments. B. A clonogenic assay was performed on TOV112D and YDOV-151 cells for 3 weeks. Left panel shows representative 
images; and right panel shows quantification of colonies. Error bars represent mean ± SD of triplicate experiments. C. Cell proliferation 
was determined by WST-1 assay. Cell proliferation curves for SNU840 and OVCA429 cells at various indicated times. Error bars represent 
mean ± SD of triplicate experiments. D. A clonogenic assay was performed on SNU840 and OVCA429 cells for 3 weeks. Left panel shows 
representative images; right panel shows quantification of colonies. Error bars represent mean ± SD of triplicate experiments. E. Soft-agar 
colony formation assay was performed using TOV112D cells. Left panel shows a representative picture; right panel shows quantification 
of colonies. Error bars represent mean ± SD of triplicate experiments. An asterisk (*) indicates a p-value < 0.05, and a double asterisk (**), 
a p-value < 0.01.
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Figure 4: S100A14 promotes cell migration and invasion. A. Cell migration analyses of TOV112D and SNU 840 cells by wound 
healing assay. Left panel: Representative images of migrations assays. Right panel: Quantitative results of migration experiments. Results 
are presented as relative migration area. B-D. Cell invasion analysis of untreated EOC cells (B), TOV112D (C), YDOV-151 (C) and 
OVCA429 (D) cells using Matrigel invasion assay. Left panel: Representative figures of cell invasion. Right panel: Quantitative results 
of invasion experiments. Results are presented as relative number of invading cells. Cells were counted in 4 randomly selected fields. An 
asterisk (*) indicates a p-value < 0.05, and a double asterisk (**), a p-value < 0.01.
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S100A14 overexpression in TOV112D cells 
increases tumor growth in nude mice xenografts 
To explore whether S100A14 can affect tumor 
growth in vivo, we inoculated TOV112D (S100A14 #6, 
#8, Empty #4, #5) as xenografts into nude mice (Fig. 
5A). Tumor volume and weight were measured. Mean 
tumor volumes (1998.5±397.0 and 1442.4±491.7 mm3, 
respectively) at day 49 in mice receiving S100A14-
overexpressed TOV112D (S100A14 #6, #8) cells were 
significantly larger than those (114.8±97.8 and 86.3±64.7 
mm3, respectively) in mice receiving empty vector-
expressing cells (Empty #4, #5) (P < 0.001) (Fig. 5B-
D). Tumor weight correlated with tumor volume, as 
determined by calipers (P < 0.001; r2 = 0.935) (Fig. 5D). 
These data indicated that S100A14 can promote tumor 
growth in vivo and further support our initial hypothesis 
that S100A14 plays a functional role in the malignant 
transformation of EOC.
S100A14 promotes a malignant phenotype in EOC 
cells through the PI3K/Akt signaling pathway
To determine the mechanism by which S100A14 
promotes a malignant phenotype in ovarian cells, we 
assessed the status of important signaling cascades 
controlled by Akt and Erk in S100A14-overexpressed 
and S100A14-shRNA-knockdown cells. S100A14 
overexpression in TOV112D (S100A14 #6, #8) and 
YDOV-151 (S100A14 #6, #10) cells led to increased 
pAkt expression (Fig. 6A), while S100A14 knockdown 
in SNU840 (sh-S100A14 #2, #5) and OVCA429 (sh-
S100A14 #2, #5) cells led to decreased pAkt expression 
(Fig. 6B). There was no detectable change, however, in 
either pErk or Erk expression after S100A14 transduction. 
To confirm the relationship between S100A14 and pAkt, 
we prepared immunoblots in a series of non-transfected 
EOC cells. TOV112D and YDOV-151 cells, which lack 
endogenous S100A14 expression, showed lower levels of 
pAkt expression compared to cells with higher endogenous 
S100A14 expression (Fig. 6C). These data suggest that 
S100A14 could potentially modulate the activity of Akt.
To define the role of Akt in S100A14-modulated 
cell proliferation and invasion, we treated TOV112D 
(S100A14 #6, #8) cells with either a PI3K (Akt upstream 
kinase) inhibitor, wortmannin, or an Akt inhibitor, MK-
2206, and evaluated their effects on cell proliferation 
and invasion. First, we confirmed the specificity of these 
inhibitors by immunoblot (Fig. 6D), wherein increased 
levels of pAkt in S100A14-overexpressed cells were 
significantly decreased by both wortmannin and MK-
2206. Next, we observed that wortmannin and MK-2206 
both significantly decreased S100A14-enhanced cell 
proliferation and invasion via colony formation assay and 
invasion assay (Fig. 6E and 6F). Taken together, these data 
Figure 5: S100A14 overexpression increases in vivo 
xenograft tumor growth. A. For the xenograft, a total of 
1.5x106 cells were injected subcutaneously into the left and 
right flank, respectively. B. Representative microCT images 
of mice seven weeks after injection. C. Gross images of 
tumor masses from representative mice from each group. D. 
S100A14 overexpression increased tumor volume and weight of 
xenografted TOV112D cells in BALB/c-nu mice. Mean tumor 
volume and weight for each group was calculated at seven 
weeks after injection. Error bars were calculated as standard 
error of means, and two-way ANOVA was used for statistical 
analyses (n = 5 mice/group). A double asterisk (**) indicates a 
p-value < 0.01.
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Figure 6: S100A14 controls oncogenic phenotypes of EOC cells through PI3K/Akt pathway. A and B. Expression of 
pAkt (ser478), Akt, pERK (thr201/204), and ERK was assessed by immunoblot in TOV112D and YDOV-151 cells (A) and SNU840 
and OVCA429 cells (B). C. Protein levels of S100A14, pAkt (ser478), and Akt were determined by immunoblot in non-transfected EOC 
cells. GAPDH was included as an internal loading control. D. Immunoblot analysis of pAkt inhibition in TOV112D cells treated with 
wortmannin, MK-2206, or control (DMSO) for eight hours. E. A clonogenic assay was performed on TOV112D cells for three weeks in 
the presence of wortmannin, MK-2206, or control (DMSO). Left panel shows representative images, and right panel shows quantification 
of colonies. Error bars represent mean ± SD of triplicate experiments. F. Cell invasion analysis of TOV112D cells with wortmannin, MK-
2206, or control (DMSO). All drugs were applied to the upper chamber. Left panel: Representative figures of cell invasion. Right panel: 
Quantitative results of invasion experiments. Results are presented as relative number of invading cells. Cells were counted in six randomly 
selected fields. A double asterisk (**) indicates a p-value < 0.01.
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demonstrate that S100A14 controls the invasive potential 
and proliferative ability of cells through regulation of the 
PI3K/Akt pathway.
DISCUSSION
In addition to identifying novel diagnostic markers 
for ovarian cancer, further understanding of the molecular 
mechanisms underlying the progression and metastasis 
of ovarian cancer is needed to develop more effective 
therapeutic treatments. Among various genes and proteins 
previously identified to be expressed or modified in 
ovarian cancer[17], S100A14 attracted research interest 
due to its marked and consistent overexpression in all six 
EOC cell lines and its reported role in cell growth and 
survival in other cancers [18-20]. In the present study, we 
investigated the functional role and clinical significance 
of S100A14 expression in ovarian cancer using EOC cell 
lines and mouse xenograft models.
It has recently been proposed that ovarian cancer 
can be divided into two main categories, type I and type 
II tumors, based on their distinct pathogenesis[21]. Type 
I tumors include well-differentiated serous, mucinous, 
endometrioid, malignant Brenner, and clear cell tumors 
that generally exhibit slow, indolent growth with 
Ras and/or Raf mutations. In contrast, type II tumors 
include moderately or poorly differentiated serous, 
undifferentiated, and malignant mixed mesodermal tumors 
with p53 mutation. Type II tumors are highly aggressive 
and present at an advanced stage, where currently 
available therapies are seldom curative[22]. When we 
consider the fact that type II tumors are more aggressive 
than type I tumors and constitute approximately 75% 
of ovarian cancer [23], it is reasonable to focus on type 
II tumors when identifying potential biomarkers in the 
future. We therefore performed subgroup analyses of 
IHC results in type I and type II tumors to compare the 
molecular subtypes of ovarian cancer. S100A14 protein 
expression was greater in type II tumors (IHC score 
= 5.42, n = 52) when compared to type I tumors (IHC 
score = 4.85, n = 19) (P < 0.001). Although the difference 
was small in our study, subsequent analysis using more 
samples may demonstrate a significant difference in 
S100A14 expression between type I and type II tumors. 
Notably, S100A14+ status and advanced tumor stage were 
independent prognostic factors for both disease-free and 
overall survival on multivariate analysis (Table 1). Taken 
together, these results suggest that S100A14 may play an 
important role in the pathogenesis of EOC. However, it 
should be noted that our relatively small clinical sample 
size is a limitation of this study and that the small sample 
size and mixture of different histological subtypes may 
weaken the strength of our clinical analysis. We therefore 
plan to incorporate larger numbers of specific histological 
subgroups to generalize our findings in a future study.
Increasing evidence suggests a critical role for 
the S100 family in cell growth, invasion, and cancer 
metastasis. We therefore investigated the potential roles 
of S100A14 in EOC based on our prior analysis of 
clinical specimens. S100A14 overexpression resulted in 
significant increases in cell proliferation and clonogenicity. 
Conversely, S100A14 knockdown led to the suppression 
of these phenotypes (Fig. 3). Importantly, S100A14 
expression positively correlated with cell migration and 
invasion in EOC cell in vitro cultures (Fig. 4) and in vivo 
xenograft-bearing mice (Fig. 5). Another limitation of 
our study should be noted, however. Only subcutaneous 
xenograft models were used to investigate EOC cell 
behavior in vivo. Cancer cells implanted subcutaneously 
allow for rapid and quantitative tumor formation, 
being more suitable for studies that require continuous 
measurement of the tumor. In contrast, intraperitoneal 
or orthotopic xenograft models are inherently difficult 
to quantitatively monitor tumor growth, but can provide 
a more relevant tumor microenvironment. Despite this 
limitation, our findings suggest that S100A14 is one of 
the critical proteins contributing to EOC carcinogenesis 
and progression.
Interestingly, there was a discrepancy in the level of 
S100A14 expression (Fig. 2A) with the gain of phenotype, 
such as cell growth (Fig. 3A), colony formation (Fig. 
3E), migration (Fig. 4A), and invasion (Fig. 4C) in 
S100A14-transfected TOV112D and YDOV-151 stable 
cell lines. There may be many reasons for the observed 
discrepancy, such as the characteristics of the cell line 
itself (e.g., TOV112D originates from endometrioid EOC 
and YDOV-151 is from mucinous EOC), cell shape, and 
cellular localization of S100A14. It is well known that the 
function of protein could be controlled by cell shape or 
its subcellular localization [24,25]. Thus, it will be very 
useful to examine cell morphology and/or subcellular 
localization of S100A14 in TOV112D and YDOV-151 
stable cell lines in future studies.
It is well known that some S100 proteins regulate 
cell invasion and metastasis by modulating expression 
and activity of MMPs [11,16,33]. In particular, Chen et al. 
reported that S100A14 promotes cell motility and invasion 
by regulating the expression and function of MMP2 in 
a p53-dependent manner in esophageal squamous cell 
carcinoma [25]. In the present study, MMP1 and MMP9 
expression was enhanced in S100A14-overexpressed 
TOV112D cells (Supplementary Fig. 2A-2B). However, 
S100A14 overexpression did not increase the expression 
of p53 in TOV112D cells (Supplementary Fig. 2C-D). 
We believe that this is mainly because of TOV112D’s 
p53R175 mutant status (http://www.atcc.org/products/all/
CRL-11731.aspx#characteristics). In contrast to our study, 
Sapkota et al. demonstrated that S100A14 overexpression 
was associated with suppression of MMP9 gelatinolytic 
activity in CaLH3 cells[16]. Thus, the function of 
S100A14 can be different depending on the anatomical 
origin of these malignant cells.
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Finally, we investigated whether Akt or Erk 
signaling pathway is compromised upon S100A14 
overexpression or knockdown. There was an obvious 
relationship between increased levels of phosphorylated 
Akt and overexpression of S100A14 in TOV112D 
and YDOV-151 cells (Fig. 6A). Conversely, S100A14 
knockdown decreased phosphorylated Akt in SNU840 
and OVCA429 cells (Fig. 6B). However, there was no 
detectable change in either expression or activation of 
Erk1/2 after S100A14 modulation (Fig. 6A-B). Inhibition 
of PI3K/Akt signaling with wortmannin or MK-2206 
resulted in significant decreases in phosphorylated Akt 
(Fig. 6D), cell proliferation (Fig. 6E), and cell invasion 
(Fig. 6F) in TOV112D or YDOV-151 cells. Thus, 
S100A14 may contribute to the malignant phenotype of 
EOC cells through activated PI3K/Akt signaling.
In summary, we demonstrate that S100A14 
expression was lowest in normal ovarian epithelium, 
slightly increased in benign and borderline ovarian 
tumors, and highest in EOC. Enhanced S100A14 
expression correlated positively with clinicopathological 
parameters in both in vitro and in vivo ovarian cancer 
systems, lending support for the use of S100A14 to 
determine clinicopathological stage and/or prognosis in 
ovarian cancer. In addition, S100A14 could be a potential 
therapeutic target, as the present study demonstrated the 
mechanistic role of S100A14 in promoting cell motility 
and invasion through the PI3K/Akt pathway. 
METHODS
Cell lines and reagents
Five EOC cell lines (YDOV-13, YDOV-151, 
YDOV-139, YDOV-161, and YDOV-13) and 6 human 
ovarian surface epithelial (HOSE) cells, which were 
established and characterized in our laboratory, were 
cultured as described previously [28,29]. SNU-840 was 
purchased from Korean Cell Line Bank (KCLB, Seoul, 
Korea). RMUG-S was purchased from Health Science 
Research Resources Bank (HSRRB, Osaka, Japan). 
SKOV3, TOV112D, OVCA429, and OVCA433 cell lines 
were purchased from American Type Culture Collection 
(ATCC, Manassas, VA). All purchased cell lines were 
maintained as recommended. AKT inhibitor MK-2206 
was purchased from Sellect (Houston, TX), and PI3 kinase 
inhibitor wortmannin was purchased from Sigma Aldrich 
(St. Louis, MO). The stock solutions of 10 mM MK-
2206 and 1 mM wortmannin were dissolved in dimethyl 
sulfoxide (DMSO). 
Patients and tumor specimens
Tumor samples from 71 EOCs (54 serous, 6 
mucinous, 4 endometrioid, 2 transitional cell, 2 mixed, 
2 clear cell, and 1 Brenner tumor), 10 borderline 
ovarian tumors (6 serous and 4 mucinous), 10 mucinous 
cystadenomas, and 13 normal ovary specimens were 
included in this study and were provided by the Korea 
Gynecologic Cancer Bank through Bio & Medical 
Technology Development Program of the Ministry of 
Education, Science and Technology, Korea. Tumor staging 
was performed according to the International Federation 
of Gynecology and Obstetrics (FIGO) classification. 
All FIGO Stage I/II ovarian cancer patients underwent 
pelvic and para-aortic lymph node dissection according 
to the National Comprehensive Cancer Network 
(NCCN) clinical practice guidelines. Medical records 
were reviewed to collect data including age, surgical 
procedure, survival time, and survival status. Response to 
therapy was assessed according to Response Evaluation 
Criteria in Solid Tumors (RECIST; version 1.0) by spiral 
computed tomography [30]. Data for tumor grades and 
cell types were obtained by reviewing pathology reports. 
All biological samples were obtained with appropriate 
informed consent from participants according to 
institutional review board (IRB) guidelines. 
Immunohistochemistry 
Paraffin tissue sections were deparaffinized in two 
changes of xylene, rehydrated in graded ethanol, and 
treated for 30 min with 3% H2O2 solution in methanol to 
block endogenous peroxidase. After blocking in 10% goat 
serum in TBS for 30 minutes, sections were incubated 
with rabbit polyclonal anti-Human S100A14 antibody 
(Proteintech Group, Inc., Chicago, IL) diluted to 1:100 
for 1 hr at room temperature, followed by detection using 
Dako LSAB+ (Dako, Glostrup, Denmark). The reaction 
product was developed with DAB (3,3’-diaminobenzidine) 
chromogen solution (Dako). Sections were counterstained 
with hematoxylin and mounted in Faramount aqueous 
mounting medium (Dako). Appropriate negative 
and positive controls were concurrently performed. 
Representative photomicrographs were recorded using a 
digital camera (Nikon, Tokyo, Japan). Negative controls 
were processed by omitting the primary antibody. Human 
pancreas tissue was used as a positive control for S100A14 
immunoreactivity.
Staining for S100A14 was scored as positive 
when tumor or epithelial cells showed cytoplasmic 
immunoreactivity. S100A14 staining results were scored 
based on staining intensity (0 = negative, 1 = weak, 2 = 
moderate, 3 = strong) and the percentage of positive cells 
(0 = 0%, 1 = 1 – 25%, 2 = 26 – 50%, 3 = 51 – 100% 
positive cells), as described previously [31]. For the 
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immunostaining score, the intensity and positivity scores 
were added, resulting in a value between 0 and 6. The 
overall score for each patient was further simplified by 
dichotomizing as either negative (overall score of ≤ 5) or 
positive (score of 6). Slides were scored in the absence of 
any clinical data, and the final immunostaining score was 
the average score of three expert pathologists. 
Real-time PCR
Total RNA was extracted using an RNeasy Mini 
Kit (Qiagen, Valencia, CA). cDNA was generated using 
a SuperScript TM III First–Strand Synthesis System 
(Invitrogen, Carlsbad, CA). Real-time PCR was performed 
to quantify messenger RNA expressions using SYBR® 
Green PCR Master Mix (Applied Biosystems, Foster 
City, CA) and the ABI PRISM® 7300 real-time PCR 
system (Applied Biosystems). A housekeeping gene, 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 
was used to normalize the quantity of cDNA used in the 
PCR reaction. Each assay was performed in triplicate 
and expressed as the mean ± SD. The primers used for 
the PCR analysis were as follows: for S100A14 forward 
5’-GTG TCG GTC AGC CAA CGC AGA-3’, S100A14 
reverse 5’-TGC TGG GTG ACC AGG TCC CGT-3’, 
MMP1 forward 5’-CTG CTG CTG CTG TTC TGG GGT-
3’, MMP1 reverse 5’-CCA CTG GGC CAC TAT TTC 
TCC GCT-3’, MMP2 forward 5’- GAT ACC CCT TTG 
ACG GTA AGG A -3’, MMP2 reverse 5’CCT TCT CCC 
AAG GTC CAT AGC -3’, MMP9 forward 5’- AGA CGG 
GTA TCC CTT CGA CG -3’, MMP9 reverse 5’- AAA 
CCG AGT TGG AAC CAC GAC -3’, GAPDH forward 
5’- GAA GGT GAA GGT CGG AGT -3’, GAPDH reverse 
5’- GAA GAT GGT GAT GGG ATT TC -3’. The primer 
for TP53 was purchased from Bioneer (Daejeon, Korea; 
Cat.# P188330). The comparative CT method was used 
to calculate relative quantification of gene expression as 
described previously [32]. 
Transfection and generation of stable cell lines
To generate pCDH/S100A14, cDNA encoding 
human S100A14 was amplified from pOTB7 S100A14 
cDNA clone (MHS1011-60727, Open Biosystems) using 
the primer set 5’-TTC TAG AGC CAC CAT GGG ACA 
GTG TCG GTC AG-3’ (forward) and 5’-TTG CGG 
CCG CTC AGT GCC CCC GGA CAG-3’ (reverse). The 
amplified cDNA was cloned into Not I /Xba I restriction 
sites of the pCDH-Promoter-MCS-EF1 Lentivector 
(System Biosciences, Mountain View, CA). Stable cell 
lines expressing S100A14 in TOV112D and YDOV-
151 were generated using the pPACKH1 Lentivector 
Packaging Kit (System Biosciences), and selection of 
S100A14-transduced cells was accomplished using 2.0 
μg/mL puromycin (Invitrogen).
For the generation of sh-S100A14 stable 
cell lines, pLKO.1 S100A14 shRNA libraries were 
purchased from Open Biosystems (Waltham, MA). 
Of five lentiviral constructs tested, two with the best 
knockdown efficiency were used for the experiments 
presented here, using the human S100A14 sequence 
ATCACTGAATTCCTGAGCATC for shRNA #2 and 
TGGTGAAAGTTCTTGATGAGG for shRNA #5. The 
non-target shRNA control vector (SHC002) was purchased 
from Sigma (Sigma Aldrich). Stable cell lines expressing 
sh-S100A14 were generated using the viral packaging 
plasmids composed of pCMV delta and pMDG. Virus 
particles were collected after 48 hours and 72 hours 
post-transfection. SNU840 and OVCA 429 cells were 
transduced, and positively transduced cells were selected 
with puromycin (2 μg/mL). 
Immunoblotting
Whole cell extraction was conducted using PRO-
PRE Protein Extraction Solution (Intron Biotechnology, 
Seongnam, Korea). Equal amounts (20 µg) of each 
sample were separated on 8-15% SDS-PAGE and 
transferred to nitrocellulose membranes. The membranes 
were blocked with 5% nonfat dry milk in TBST (50 
mM Tris, 150 mM NaCl, 0.1% Tween-20, pH 7.5) 
for 1 hr at room temperature, washed with TBST, and 
subsequently incubated with primary antibodies: anti-
S100A14 (Proteintech, Chicago, IL), anti-phospho-Akt 
(ser473), anti-Akt, anti-phospho-Erk1/2, anti-Erk1/2 
(Cell Signaling, Danvers, MA), anti-TP53 (Santa Cruz 
Biotechnology, Santa Cruz, CA) and anti-GAPDH 
(Santa Cruz Biotechnology). Primary antibodies against 
each protein were detected by secondary antibodies 
conjugated with horseradish peroxidase (GE Healthcare, 
Munich, Germany). Specific bands for each protein were 
detected on AGFA X-ray film (Agfa Health Care, Mortsel, 
Belgium) using the SuperSignal Chemiluminescence kit 
(Thermo Scientific, Rockford, IL).
Cell growth and clonogenicity 
Cell proliferation was measured by WST-1 assay 
(DaeilLab, Seoul, Korea). In brief, cells were seeded at 
3×103 viable cells/well onto 96-well microtiter plates 
in a final volume of 100 μL/well. Cells were incubated 
with WST-1 at 37oC for 2 hours and optical density (OD) 
values at 450 nm were recorded at days 0, 3, and 5 using 
a 96-well microplate reader (Bio-Rad Laboratories, 
Inc., Hercules, CA). The experiment was performed in 
triplicate.
In order to examine clonogenicity, cells were 
seeded into 60-mm dishes (0.02-0.1×104 cells/well) and 
cultured for 3 weeks. Colonies formed in each well were 
fixed with H2O containing 10% methanol and 10% acetic 
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acid, stained with 0.5% crystal violet, and then counted 
visually. A three-dimensional clonogenic growth assay 
was performed using a soft agar culture system. Briefly, 
cells were mixed in 0.3% agar containing 10% FBS and 
layered on top of the base layer of 0.6% agar in a 60-mm 
dish (3×103 cells/dish). After a four-week incubation in a 
humidified CO2 incubator, colonies were counted visually 
after staining with 0.5% crystal violet. Each cell group was 
cultured in triplicate, and colonies greater than 1.5 mm in 
diameter were scored visually.
Cell migration and invasion assays 
Cell migration was assessed by monolayer wound 
healing assay [33]. Briefly, cells were seeded into 12-
well tissue culture dishes and allowed to grow to 90% 
confluency in complete medium. Cell monolayers were 
wounded with a plastic pipette tip (1 mm), and washed 
four times with complete medium to remove cell debris. 
After 24 hours of culture, phase contrast images were 
captured of the gap in the monolayers (EVOS®FL Cell 
Imaging System, Life Technologies, Carlsbad, CA). A 
cell invasion assay was performed in an invasion chamber 
(Neuro Probe 48-Well Micro Chemotaxis Chamber, 
Neuro Probe, Inc., Gaithersburg, MD) according to the 
manufacturer’s instruction. In brief, 5×104 cells were 
resuspended in serum-free medium (56 μL) and plated 
onto the upper chamber coated with Matrigel (BD 
Transduction Lab, San Jose, CA). The lower chamber was 
filled with medium containing 0.1-10% FBS (27 μL). After 
24 hours of incubation, cells that had migrated through 
the membrane were stained with the Differential Quik 
Stain Kit (Triangle Biomedical Sciences, Inc., Durham, 
NC). Invading cells in six randomly selected fields were 
counted using Microscope Axio Imager.M2 (Carl Zeiss, 
Thornwood, NY, Magnification x200). Each experiment 
was repeated three times.
Animal studies
All animal procedures were performed under a 
protocol approved by the Institutional Animal Care and 
Use Committee of Gangnam Severance Hospital. A mouse 
ovarian cancer xenograft model was established using 
female BALB/C nude mice aged 4-5 weeks (OrientBio 
Inc., Sungnam, Gyunggi, Korea). TOV112D cells 
(1.5×106 cells/inoculation) were resuspended in 100 μL 
of a Matrigel (BD Biosciences, QC) and PBS mixture 
(1:1) and inoculated subcutaneously in both left and right 
flanks of each mouse. Seven weeks after inoculation, 
tumor-bearing mice were subjected to microCT imaging 
(NFR Polaris-G90 Micro CT scanner, Nano Focus Ray, 
Jeonju, Chunbuk, Korea). Briefly, mice were anesthetized 
using isoflurane/O2 (1.5-5% v/v) gas and scanned with 
the following parameter settings: 360 scan angle, X-ray 
voltage 65 kV, X-ray current 115 μA, X-ray spot size 9 
μm, binning 1, and exposure time 40 ms. After microCT 
imaging, tumors were harvested from each mouse, 
weighted, and fixed in 10% neutral buffered formalin 
for histological assays. Tumor volumes were calculated 
using the following formula: tumor volume (mm3) = (L x 
W2)/2, where L is the length and W is width [34]. Data is 
represented as means ± standard errors. 
Statistical analysis
Normality of distribution was assessed using the 
Shapiro-Wilk test. Because the distribution was not 
normal, univariate comparisons for quantitative variables 
between normal and cancerous specimens were made 
using non-parametric statistics (Kruskal–Wallis and 
Mann–Whitney U) where appropriate. Results with two-
tailed p-values less than 0.05 were considered statistically 
significant. Statistical analyses were performed using 
SPSS software version 18.0 (SPSS Inc., Chicago, IL).
ACKNOWLEDGEMENTS
The authors thank Prof. Yong Il Kwon, Prof. Jong-
Hyeok Kim, Prof. Nam Hoon Cho, and Prof. Jae Yong 
Cho for their assistance on technical aspects of this study 
and editing. 
GRANT SUPPORT
This work was supported in part by grants from the 
Basic Science Research Program through the National 
Research Foundation of Korea (NRF), funded by the 
Ministry of Education, Science and Technology (2010-
0011153, 2011-0010286, and 2011-0007146), the Korea 
Healthcare Technology R&D Project, Ministry for Health 
& Welfare Affairs, Republic of Korea (A121387), and 
faculty research grants from Yonsei University College of 
Medicine for 2013 (6-2013-0106).
CONFLICT OF INTEREST STATEMENT
The authors declare that there are no conflicts of 
interest.
REFERENCES
1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. 
Cancer statistics, 2007. CA Cancer J Clin. 2007; 57(1): 43-
66.
2. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC. 
Ovarian surface epithelium: biology, endocrinology, and 
pathology. Endocr Rev. 2001; 22(2): 255-288.
3. Kuhn E, Kurman RJ, Vang R, Sehdev AS, Han G, Soslow 
Oncotarget3495www.impactjournals.com/oncotarget
R, Wang TL, Shih Ie M. TP53 mutations in serous tubal 
intraepithelial carcinoma and concurrent pelvic high-
grade serous carcinoma--evidence supporting the clonal 
relationship of the two lesions. J Pathol. 2012; 226(3): 421-
426.
4. Finch A, Shaw P, Rosen B, Murphy J, Narod SA, Colgan 
TJ. Clinical and pathologic findings of prophylactic 
salpingo-oophorectomies in 159 BRCA1 and BRCA2 
carriers. Gynecol Oncol. 2006; 100(1): 58-64.
5. Piek JM, Kenemans P, Verheijen RH. Intraperitoneal serous 
adenocarcinoma: a critical appraisal of three hypotheses on 
its cause. Am J Obstet Gynecol. 2004; 191(3): 718-732.
6. Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-
Keesom RJ, Menko FH, Gille JJ, Jongsma AP, Pals 
G, Kenemans P, Verheijen RH. Dysplastic changes in 
prophylactically removed Fallopian tubes of women 
predisposed to developing ovarian cancer. J Pathol. 2001; 
195(4): 451-456.
7. Donato R. S100: a multigenic family of calcium-modulated 
proteins of the EF-hand type with intracellular and 
extracellular functional roles. Int J Biochem Cell Biol. 
2001; 33(7): 637-668.
8. Donato R. Intracellular and extracellular roles of S100 
proteins. Microsc Res Tech. 2003; 60(6): 540-551.
9. Marenholz I, Heizmann CW, Fritz G. S100 proteins in 
mouse and man: from evolution to function and pathology 
(including an update of the nomenclature). Biochem 
Biophys Res Commun. 2004; 322(4): 1111-1122.
10. Salama I, Malone PS, Mihaimeed F, Jones JL. A review of 
the S100 proteins in cancer. Eur J Surg Oncol. 2008; 34(4): 
357-364.
11. Saleem M, Kweon MH, Johnson JJ, Adhami VM, Elcheva 
I, Khan N, Bin Hafeez B, Bhat KM, Sarfaraz S, Reagan-
Shaw S, Spiegelman VS, Setaluri V, Mukhtar H. S100A4 
accelerates tumorigenesis and invasion of human prostate 
cancer through the transcriptional regulation of matrix 
metalloproteinase 9. Proc Natl Acad Sci U S A. 2006; 
103(40): 14825-14830.
12. Whiteman HJ, Weeks ME, Dowen SE, Barry S, Timms JF, 
Lemoine NR, Crnogorac-Jurcevic T. The role of S100P in 
the invasion of pancreatic cancer cells is mediated through 
cytoskeletal changes and regulation of cathepsin D. Cancer 
Res. 2007; 67(18): 8633-8642.
13. Bulk E, Sargin B, Krug U, Hascher A, Jun Y, Knop M, 
Kerkhoff C, Gerke V, Liersch R, Mesters RM, Hotfilder M, 
Marra A, Koschmieder S, Dugas M, Berdel WE, Serve H, 
Muller-Tidow C. S100A2 induces metastasis in non-small 
cell lung cancer. Clin Cancer Res. 2009; 15(1): 22-29.
14. Pietas A, Schluns K, Marenholz I, Schafer BW, Heizmann 
CW, Petersen I. Molecular cloning and characterization of 
the human S100A14 gene encoding a novel member of the 
S100 family. Genomics. 2002; 79(4): 513-522.
15. Yao R, Lopez-Beltran A, Maclennan GT, Montironi R, Eble 
JN, Cheng L. Expression of S100 protein family members 
in the pathogenesis of bladder tumors. Anticancer Res. 
2007; 27(5A): 3051-3058.
16. Sapkota D, Bruland O, Costea DE, Haugen H, Vasstrand 
EN, Ibrahim SO. S100A14 regulates the invasive potential 
of oral squamous cell carcinoma derived cell-lines in vitro 
by modulating expression of matrix metalloproteinases, 
MMP1 and MMP9. Eur J Cancer. 2011; 47(4): 600-610.
17. Cho H, Lee YS, Kim J, Chung JY, Kim JH. Overexpression 
of glucose transporter-1 (GLUT-1) predicts poor prognosis 
in epithelial ovarian cancer. Cancer Invest. 2013; 31(9): 
607-615.
18. Chen H, Ma J, Sunkel B, Luo A, Ding F, Li Y, He H, 
Zhang S, Xu C, Jin Q, Wang Q, Liu Z. S100A14 is a 
novel modulator of terminal differentiation of esophageal 
squamous cell carcinoma. Mol Cancer Res. 2013; 
doi:10.1158/1541-7786.mcr-13-0317.
19. Sapkota D, Costea DE, Ibrahim SO, Johannessen AC, 
Bruland O. S100A14 Interacts with S100A16 and Regulates 
Its Expression in Human Cancer Cells. PLoS One. 2013; 
8(9): e76058.
20. Xu C, Chen H, Wang X, Gao J, Che Y, Li Y, Ding F, 
Luo A, Zhang S, Liu Z. S100A14,a member of EF-hand 
Calcium-Binding Proteins, is overexpressed in breast cancer 
and acts as a modulator of HER2 signaling. J Biol Chem. 
2013; doi:10.1074/jbc.M113.469718.
21. Shih Ie M, Kurman RJ. Ovarian tumorigenesis: a proposed 
model based on morphological and molecular genetic 
analysis. Am J Pathol. 2004; 164(5): 1511-1518.
22. Kurman RJ, Visvanathan K, Roden R, Wu TC, Shih Ie M. 
Early detection and treatment of ovarian cancer: shifting 
from early stage to minimal volume of disease based on a 
new model of carcinogenesis. Am J Obstet Gynecol. 2008; 
198(4): 351-356.
23. Kurman RJ, Shih Ie M. The origin and pathogenesis of 
epithelial ovarian cancer: a proposed unifying theory. Am J 
Surg Pathol. 2010; 34(3): 433-443.
24. Yu CS, Chen YC, Lu CH, Hwang JK. Prediction of protein 
subcellular localization. Proteins. 2006; 64(3): 643-651.
25. Huang S, Ingber DE. Shape-dependent control of cell 
growth, differentiation, and apoptosis: switching between 
attractors in cell regulatory networks. Exp Cell Res. 2000; 
261(1): 91-103.
26. Moon A, Yong HY, Song JI, Cukovic D, Salagrama S, 
Kaplan D, Putt D, Kim H, Dombkowski A, Kim HR. Global 
gene expression profiling unveils S100A8/A9 as candidate 
markers in H-ras-mediated human breast epithelial cell 
invasion. Mol Cancer Res. 2008; 6(10): 1544-1553.
27. Chen H, Yuan Y, Zhang C, Luo A, Ding F, Ma J, Yang S, 
Tian Y, Tong T, Zhan Q, Liu Z. Involvement of S100A14 
protein in cell invasion by affecting expression and function 
of matrix metalloproteinase (MMP)-2 via p53-dependent 
transcriptional regulation. J Biol Chem. 2012; 287(21): 
17109-17119.
28. Cho H, Kang ES, Hong SW, Oh YJ, Choi SM, Kim SW, 
Oncotarget3496www.impactjournals.com/oncotarget
Kim SH, Kim YT, Lee KS, Choi YK, Kim JH. Genomic 
and proteomic characterization of YDOV-157, a newly 
established human epithelial ovarian cancer cell line. Mol 
Cell Biochem. 2008; 319(1-2): 189-201.
29. Cho H, Lim BJ, Kang ES, Choi JS, Kim JH. Molecular 
characterization of a new ovarian cancer cell line, YDOV-
151, established from mucinous cystadenocarcinoma. 
Tohoku J Exp Med. 2009; 218(2): 129-139.
30. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, 
Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, 
van Oosterom AT, Christian MC, Gwyther SG. New 
guidelines to evaluate the response to treatment in solid 
tumors. European Organization for Research and Treatment 
of Cancer, National Cancer Institute of the United States, 
National Cancer Institute of Canada. J Natl Cancer Inst. 
2000; 92(3): 205-216.
31. Shibusa T, Shijubo N, Abe S. Tumor angiogenesis and 
vascular endothelial growth factor expression in stage I lung 
adenocarcinoma. Clin Cancer Res. 1998; 4(6): 1483-1487.
32. Livak KJ, Schmittgen TD. Analysis of relative gene 
expression data using real-time quantitative PCR and the 
2(-Delta Delta C(T)) Method. Methods. 2001; 25(4): 402-
408.
33. Valster A, Tran NL, Nakada M, Berens ME, Chan AY, 
Symons M. Cell migration and invasion assays. Methods. 
2005; 37(2): 208-215.
34. Goodwin SC, Bonilla SC, Sacks D, Reed RA, Spies JB, 
Landow WJ, Worthington-Kirsch RL. Reporting standards 
for uterine artery embolization for the treatment of uterine 
leiomyomata. J Vasc Interv Radiol. 2003; 14(9 Pt 2): S467-
476.
